Evidence map›Paper›PMID 29922598›Full record

ArticleFrontiers in cellular and infection microbiology2018

New Application of Psoralen and Angelicin on Periodontitis With Anti-bacterial, Anti-inflammatory, and Osteogenesis Effects.

Xiaotian Li, Chunbo Yu, Yi Hu, Xinyi Xia, Yue Liao, Jing Zhang, Huiwen Chen, Weili Lu, Wei Zhou, Zhongchen Song

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 108 citations in OpenAlex.

  1. Journal of xenobiotics · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Frontiers in cellular and infection microbiology · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xiaotian LiDepartment of Periodontology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chunbo YuNinth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yi HuDepartment of Periodontology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xinyi XiaDepartment of Periodontology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yue LiaoDepartment of Periodontology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jing ZhangDepartment of Periodontology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huiwen ChenDepartment of Periodontology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weili LuDepartment of Periodontology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wei ZhouShanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China.
Zhongchen SongDepartment of Periodontology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Jiao Tong University · CNShanghai Ninth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoralen and angelicin are two effective compounds isolated from psoraleae, a traditional Chinese medicine. They have a wide range of applications for bone disease treatment and immune modulation. In this study, we explored their new applications for the treatment of periodontal diseases. This study aimed to investigate the effects of psoralen and angelicin on

Indexed as

Alkaline PhosphataseAlveolar Bone LossAnimalsAnti-Bacterial AgentsAnti-Inflammatory AgentsBiofilmsBone Morphogenetic ProteinsCell SurvivalCore Binding Factor Alpha 1 SubunitCytokinesDisease Models, AnimalDose-Response Relationship, DrugDrug CombinationsFicusinFurocoumarinsGene ExpressionAlkaline PhosphataseangelicinAnti-Bacterial AgentsAnti-Inflammatory AgentsBone Morphogenetic ProteinsCore Binding Factor Alpha 1 SubunitCytokinesDLX5 protein, humanDrug CombinationsFicusinFurocoumarinsHomeodomain ProteinsInterleukin-1betaInterleukin-8LipopolysaccharidesOsteopontinRNA, MessengerRUNX2 protein, humanSPP1 protein, humanTranscription Factorsangelicinanti-bacteriaanti-inflammationosteogenesispsoralen

Identifiers

PMID29922598
PMCPMC5996246
OpenAlexW2803023778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.